Filed under: kinase | Tagged: GDC-0941, GDC0941, Genentech, kinase, PI3K, Piramed, Preclinical, Research, Roche
Piramed/Genentech publish data on PI3K inhibitor GDC-0941
Posted on September 1, 2008 by crimsoncanary
Blogroll
Tags
AstraZeneca aurora Avastin bayer Bcr-Abl bevacizumab BMS c-kit cetuximab EGFR ErbB-2 ErbB2 erbitux Exelixis Genentech GlaxoSmithKline Gleevec GSK HER1 HER2 IGF-1R Imatinib ImClone JAK2 kinase Merck-Serono Met mTOR multikinase Nexavar Novartis onyx PDGF Pfizer phase I Phase II phase iii PI3K Preclinical regulatory Research Roche sorafenib VEGF VEGFR2- Providing a resource for information on kinase inhibitors
Blog at WordPress.com. Theme: Digg 3 Column by WP Designer
